CAMBRIDGE, Mass., May 16, 2019 /PRNewswire/ -- Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that
Adelene Perkins, Infinity
Pharmaceutical's Chief Executive Officer, will present at the B.
Riley FBR Institutional Investor Conference on Thursday, May 23, 2019, at 2:00 p.m. PT (5:00 p.m.
ET) at The Beverly Hilton, Beverly
Hills, CA. A live webcast of the presentation will be
available on the Investors/Media section of Infinity's website at
www.infi.com, and will be available for 30 days following the
event.
About Infinity
Infinity is an innovative
biopharmaceutical company dedicated to advancing novel medicines
for people with cancer. Infinity is advancing IPI-549, a
first-in-class, oral immuno-oncology development candidate that
selectively inhibits PI3K-gamma, in multiple clinical studies.
MARIO-1 is an ongoing Phase 1/1b
study evaluating IPI-549 as a monotherapy and in combination with
Opdivo (nivolumab) in approximately 220 patients with advanced
solid tumors including patients refractory to anti-PD-1 therapy.
Infinity intends to initiate MARIO-275, a global, randomized,
combination study of IPI-549 combined with Opdivo in I/O naïve
urothelial cancer patients in 2Q19, as well as to initiate MARIO-3,
the first IPI-549 combination study in front-line advanced cancer
patients in 2H19. MARIO-3 will evaluate IPI-549 in combination with
Tecentriq and Abraxane in front-line TNBC and in combination with
Tecentriq and Avastin in front-line RCC. With the addition of
MARIO-275 and MARIO-3 to the ongoing MARIO-1 study, Infinity will
be evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve and
front-line settings in a total of ~500 patients. For more
information on Infinity, please refer to Infinity's website
at www.infi.com.
Contact:
Stephanie
Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
View original
content:http://www.prnewswire.com/news-releases/infinity-pharmaceuticals-to-present-at-b-riley-fbr-institutional-investor-conference-300851343.html
SOURCE Infinity Pharmaceuticals, Inc.